A new ruling which forces US companies to account for stock options as expenses could penalize biotech companies. Until now, stock options have been an incentive to recruit top managers who would otherwise prefer larger companies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
https://doi.org/10.1038/Nat.Biotechnol.,22,1065-1066(2004)
https://doi.org/10.1038/Nat.Biotechnol.22,925-926(2004)
Related external links
Rights and permissions
About this article
Cite this article
Lawrence, S. Stock options could no longer be the carrot. Nat Biotechnol 23, 157 (2005). https://doi.org/10.1038/nbt0205-157
Issue date:
DOI: https://doi.org/10.1038/nbt0205-157
This article is cited by
-
Wasting cash—the decline of the British biotech sector
Nature Biotechnology (2009)
